Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Interest Expense

Cost of servicing the company's debt during the period.

Cytokinetics, IncorporatedNASDAQ: CYTK

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of $34.83M rose 43.5% year over year, ahead of the +35.5% change in trailing-twelve-month interest expense. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.

Context

  • Interest expense amounted to 118.0% of revenue in FY2025, down 350.3 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +43.5% holds above the trailing-twelve-month pace of +35.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.83M+4.5% QoQ
Last fiscal yearDec 2025
$103.87M+20.1% YoY
LTMJun 2026
$124.82M+35.5% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.5%——
1 year+20.1%——
3-year CAGR+26.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
103.87M USD
Year-over-year change
+20.1%
4-year CAGR
+37.2%

Interest Expense vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 interest expense of $124.82M is the highest of the 3 companies compared; the peer median is $0.
  • Interest expense amounts to 175.9% of revenue for CYTK, versus a peer median of 0.0%.
CYTK Competitors Peer median
Interest Expense for CYTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$124.82M +35.5%+26.6%175.9%
RNAAtrium Therapeutics, Inc.FY2025$0 ——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
KARDKardigan, Inc.—— ———
Peer median (excluding CYTK) $0——0.0%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.